The Investor
23 Oct 2025, 18:35
Vertex Highlights New Data on Cystic Fibrosis Treatments at NACFC 2025
Vertex Pharmaceuticals (Nasdaq: VRTX) presented new clinical data at the North American Cystic Fibrosis Conference (NACFC) in Seattle, showcasing the benefits of its CFTR modulators, including the latest therapy ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor).
The studies show that reductions in sweat chloride (SwCl) — a marker of improved CFTR function — correlate with better outcomes in cystic fibrosis (CF) patients, particularly children. In Phase 3 trials, ALYFTREK achieved greater sweat chloride reduction than TRIKAFTA, suggesting stronger potential improvements in lung function and quality of life.
Post-hoc analyses found fewer pulmonary exacerbations and hospitalizations for patients treated with ALYFTREK compared to TRIKAFTA. Data also confirmed that starting modulator therapy earlier in childhood yields broader clinical benefits, including better lung health and nutrition.
Vertex Pharmaceuticals (Nasdaq: VRTX) presented new clinical data at the North American Cystic Fibrosis Conference (NACFC) in Seattle, showcasing the benefits of its CFTR modulators, including the latest therapy ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor).
The studies show that reductions in sweat chloride (SwCl) — a marker of improved CFTR function — correlate with better outcomes in cystic fibrosis (CF) patients, particularly children. In Phase 3 trials, ALYFTREK achieved greater sweat chloride reduction than TRIKAFTA, suggesting stronger potential improvements in lung function and quality of life.
Post-hoc analyses found fewer pulmonary exacerbations and hospitalizations for patients treated with ALYFTREK compared to TRIKAFTA. Data also confirmed that starting modulator therapy earlier in childhood yields broader clinical benefits, including better lung health and nutrition.
